Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Ataluren use in patients with nonsense mutation Duchenne muscular dystrophy: patient demographics and characteristics from the STRIDE Registry.

Muntoni F, Desguerre I, Guglieri M, Osorio AN, Kirschner J, Tulinius M, Buccella F, Elfring G, Werner C, Schilling T, Trifillis P, Zhang O, Delage A, Santos CL, Mercuri E.

J Comp Eff Res. 2019 Aug 15. doi: 10.2217/cer-2019-0086. [Epub ahead of print]

2.

The minor gentamicin complex component, X2, is a potent premature stop codon readthrough molecule with therapeutic potential.

Friesen WJ, Johnson B, Sierra J, Zhuo J, Vazirani P, Xue X, Tomizawa Y, Baiazitov R, Morrill C, Ren H, Babu S, Moon YC, Branstrom A, Mollin A, Hedrick J, Sheedy J, Elfring G, Weetall M, Colacino JM, Welch EM, Peltz SW.

PLoS One. 2018 Oct 25;13(10):e0206158. doi: 10.1371/journal.pone.0206158. eCollection 2018.

3.

The relationship between deficit in digit span and genotype in nonsense mutation Duchenne muscular dystrophy.

Thangarajh M, Elfring GL, Trifillis P, McIntosh J, Peltz SW; Ataluren Phase 2b Study Group.

Neurology. 2018 Sep 25;91(13):e1215-e1219. doi: 10.1212/WNL.0000000000006245. Epub 2018 Aug 22.

PMID:
30135256
4.

Deflazacort versus prednisone/prednisolone for maintaining motor function and delaying loss of ambulation: A post HOC analysis from the ACT DMD trial.

Shieh PB, Mcintosh J, Jin F, Souza M, Elfring G, Narayanan S, Trifillis P, Peltz SW, Mcdonald CM, Darras BT; THE ACT DMD STUDY GROUP.

Muscle Nerve. 2018 Nov;58(5):639-645. doi: 10.1002/mus.26191. Epub 2018 Sep 27.

PMID:
30028519
5.

Propulsion via flexible flapping in granular media.

Peng Z, Ding Y, Pietrzyk K, Elfring GJ, Pak OS.

Phys Rev E. 2017 Jul;96(1-1):012907. doi: 10.1103/PhysRevE.96.012907. Epub 2017 Jul 31.

PMID:
29347182
6.

Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

McDonald CM, Campbell C, Torricelli RE, Finkel RS, Flanigan KM, Goemans N, Heydemann P, Kaminska A, Kirschner J, Muntoni F, Osorio AN, Schara U, Sejersen T, Shieh PB, Sweeney HL, Topaloglu H, Tulinius M, Vilchez JJ, Voit T, Wong B, Elfring G, Kroger H, Luo X, McIntosh J, Ong T, Riebling P, Souza M, Spiegel RJ, Peltz SW, Mercuri E; Clinical Evaluator Training Group; ACT DMD Study Group.

Lancet. 2017 Sep 23;390(10101):1489-1498. doi: 10.1016/S0140-6736(17)31611-2. Epub 2017 Jul 17.

PMID:
28728956
7.

Maximizing propulsive thrust of a driven filament at low Reynolds number via variable flexibility.

Peng Z, Elfring GJ, Pak OS.

Soft Matter. 2017 Mar 22;13(12):2339-2347. doi: 10.1039/c6sm02880b.

PMID:
28267159
8.

Phase 1 Study of Safety, Tolerability, and Pharmacokinetics of PTC299, an Inhibitor of Stress-Regulated Protein Translation.

Weetall M, Davis T, Elfring G, Northcutt V, Cao L, Moon YC, Riebling P, Dali M, Hirawat S, Babiak J, Colacino J, Almstead N, Spiegel R, Peltz SW.

Clin Pharmacol Drug Dev. 2016 Jul;5(4):296-305. doi: 10.1002/cpdd.240. Epub 2016 Feb 2.

9.

Hydrodynamic interactions of cilia on a spherical body.

Nasouri B, Elfring GJ.

Phys Rev E. 2016 Mar;93(3):033111. doi: 10.1103/PhysRevE.93.033111. Epub 2016 Mar 14.

PMID:
27078451
10.

Ataluren treatment of patients with nonsense mutation dystrophinopathy.

Bushby K, Finkel R, Wong B, Barohn R, Campbell C, Comi GP, Connolly AM, Day JW, Flanigan KM, Goemans N, Jones KJ, Mercuri E, Quinlivan R, Renfroe JB, Russman B, Ryan MM, Tulinius M, Voit T, Moore SA, Lee Sweeney H, Abresch RT, Coleman KL, Eagle M, Florence J, Gappmaier E, Glanzman AM, Henricson E, Barth J, Elfring GL, Reha A, Spiegel RJ, O'donnell MW, Peltz SW, Mcdonald CM; PTC124-GD-007-DMD STUDY GROUP.

Muscle Nerve. 2014 Oct;50(4):477-87. doi: 10.1002/mus.24332.

11.

Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.

Kerem E, Konstan MW, De Boeck K, Accurso FJ, Sermet-Gaudelus I, Wilschanski M, Elborn JS, Melotti P, Bronsveld I, Fajac I, Malfroot A, Rosenbluth DB, Walker PA, McColley SA, Knoop C, Quattrucci S, Rietschel E, Zeitlin PL, Barth J, Elfring GL, Welch EM, Branstrom A, Spiegel RJ, Peltz SW, Ajayi T, Rowe SM; Cystic Fibrosis Ataluren Study Group.

Lancet Respir Med. 2014 Jul;2(7):539-47. doi: 10.1016/S2213-2600(14)70100-6. Epub 2014 May 15.

12.

Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy.

Finkel RS, Flanigan KM, Wong B, Bönnemann C, Sampson J, Sweeney HL, Reha A, Northcutt VJ, Elfring G, Barth J, Peltz SW.

PLoS One. 2013 Dec 11;8(12):e81302. doi: 10.1371/journal.pone.0081302. eCollection 2013.

13.

The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study.

McDonald CM, Henricson EK, Abresch RT, Florence JM, Eagle M, Gappmaier E, Glanzman AM; PTC124-GD-007-DMD Study Group, Spiegel R, Barth J, Elfring G, Reha A, Peltz S.

Muscle Nerve. 2013 Sep;48(3):343-56. doi: 10.1002/mus.23902. Epub 2013 Jun 26.

14.

The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study.

McDonald CM, Henricson EK, Abresch RT, Florence J, Eagle M, Gappmaier E, Glanzman AM; PTC124-GD-007-DMD Study Group, Spiegel R, Barth J, Elfring G, Reha A, Peltz SW.

Muscle Nerve. 2013 Sep;48(3):357-68. doi: 10.1002/mus.23905. Epub 2013 Jul 17.

15.

Corticosteroids in Duchenne muscular dystrophy: major variations in practice.

Griggs RC, Herr BE, Reha A, Elfring G, Atkinson L, Cwik V, McColl E, Tawil R, Pandya S, McDermott MP, Bushby K.

Muscle Nerve. 2013 Jul;48(1):27-31. doi: 10.1002/mus.23831. Epub 2013 Apr 25.

PMID:
23483575
16.

Percent-predicted 6-minute walk distance in duchenne muscular dystrophy to account for maturational influences.

Henricson E, Abresch R, Han JJ, Nicorici A, Goude Keller E, Elfring G, Reha A, Barth J, McDonald CM.

Version 2. PLoS Curr. 2012 Jan 25 [revised 2012 Jan 1];4:RRN1297.

17.

Ambulatory quantitative waking and sleeping cough assessment in patients with cystic fibrosis.

Kerem E, Wilschanski M, Miller NL, Pugatsch T, Cohen T, Blau H, Rivlin J, Shoseyov D, Reha A, Constantine S, Ajayi T, Hirawat S, Elfring GL, Peltz SW, Miller LL.

J Cyst Fibros. 2011 May;10(3):193-200. doi: 10.1016/j.jcf.2011.02.003. Epub 2011 Apr 2.

18.

Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis.

Wilschanski M, Miller LL, Shoseyov D, Blau H, Rivlin J, Aviram M, Cohen M, Armoni S, Yaakov Y, Pugatsch T, Cohen-Cymberknoh M, Miller NL, Reha A, Northcutt VJ, Hirawat S, Donnelly K, Elfring GL, Ajayi T, Kerem E.

Eur Respir J. 2011 Jul;38(1):59-69. doi: 10.1183/09031936.00120910. Epub 2011 Jan 13. Erratum in: Eur Respir J. 2011 Oct;38(4):996. Pugatch, T [corrected to Pugatsch, T].

19.

The 6-minute walk test in Duchenne/Becker muscular dystrophy: longitudinal observations.

McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, Atkinson L, Elfring GL, Reha A, Miller LL.

Muscle Nerve. 2010 Dec;42(6):966-74. doi: 10.1002/mus.21808.

PMID:
21038378
20.

Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis.

Sermet-Gaudelus I, Boeck KD, Casimir GJ, Vermeulen F, Leal T, Mogenet A, Roussel D, Fritsch J, Hanssens L, Hirawat S, Miller NL, Constantine S, Reha A, Ajayi T, Elfring GL, Miller LL.

Am J Respir Crit Care Med. 2010 Nov 15;182(10):1262-72. doi: 10.1164/rccm.201001-0137OC. Epub 2010 Jul 9.

PMID:
20622033
21.

The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy.

McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, Elfring GL, Atkinson L, Reha A, Hirawat S, Miller LL.

Muscle Nerve. 2010 Apr;41(4):500-10. doi: 10.1002/mus.21544.

PMID:
19941337
22.

Hydrodynamic phase locking of swimming microorganisms.

Elfring GJ, Lauga E.

Phys Rev Lett. 2009 Aug 21;103(8):088101. Epub 2009 Aug 17.

PMID:
19792766
23.

Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial.

Kerem E, Hirawat S, Armoni S, Yaakov Y, Shoseyov D, Cohen M, Nissim-Rafinia M, Blau H, Rivlin J, Aviram M, Elfring GL, Northcutt VJ, Miller LL, Kerem B, Wilschanski M.

Lancet. 2008 Aug 30;372(9640):719-27. doi: 10.1016/S0140-6736(08)61168-X. Epub 2008 Aug 20.

PMID:
18722008
24.

Progression-free survival is a surrogate for survival in advanced colorectal cancer.

Buyse M, Burzykowski T, Carroll K, Michiels S, Sargent DJ, Miller LL, Elfring GL, Pignon JP, Piedbois P.

J Clin Oncol. 2007 Nov 20;25(33):5218-24.

PMID:
18024867
25.

Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers.

Hirawat S, Welch EM, Elfring GL, Northcutt VJ, Paushkin S, Hwang S, Leonard EM, Almstead NG, Ju W, Peltz SW, Miller LL.

J Clin Pharmacol. 2007 Apr;47(4):430-44.

PMID:
17389552
26.

Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.

Schaaf LJ, Hammond LA, Tipping SJ, Goldberg RM, Goel R, Kuhn JG, Miller LL, Compton LD, Cisar LA, Elfring GL, Gruia G, McGovren JP, Pirotta N, Yin D, Sharma A, Duncan BA, Rothenberg ML.

Clin Cancer Res. 2006 Jun 15;12(12):3782-91.

27.

Evaluation of lincomycin in drinking water for treatment of induced porcine proliferative enteropathy using a Swine challenge model.

Bradford JR, Winkelman NL, Moreira FP, Elfring GD.

Vet Ther. 2004 Winter;5(4):239-50.

PMID:
15719323
28.

Irinotecan (CPT-11) in triplet combinations in patients with advanced non small-cell lung cancer: a review and report of a phase I/II trial.

Socinski MA, Sandler AB, Miller LL, Locker PK, Hanover CK, Elfring GL, Israel VK, Pirotta N, Natale RB.

Clin Lung Cancer. 2001 May;2 Suppl 2:S26-33.

PMID:
14725727
29.

Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.

Cloughesy TF, Filka E, Kuhn J, Nelson G, Kabbinavar F, Friedman H, Miller LL, Elfring GL.

Cancer. 2003 May 1;97(9 Suppl):2381-6.

30.

Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma.

Socinski MA, Sandler AB, Israel VK, Gillenwater HH, Miller LL, Locker PK, Antonellini A, Elfring GL, Natale RB.

Cancer. 2002 Oct 1;95(7):1520-7.

31.

Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.

Cloughesy TF, Filka E, Nelson G, Kabbinavar F, Friedman H, Miller LL, Elfring GL.

Am J Clin Oncol. 2002 Apr;25(2):204-8.

PMID:
11943904
32.

Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer.

Rocha Lima CM, Savarese D, Bruckner H, Dudek A, Eckardt J, Hainsworth J, Yunus F, Lester E, Miller W, Saville W, Elfring GL, Locker PK, Compton LD, Miller LL, Green MR.

J Clin Oncol. 2002 Mar 1;20(5):1182-91.

PMID:
11870159
33.

Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.

Rothenberg ML, Kuhn JG, Schaaf LJ, Rodriguez GI, Eckhardt SG, Villalona-Calero MA, Rinaldi DA, Hammond LA, Hodges S, Sharma A, Elfring GL, Petit RG, Locker PK, Miller LL, von Hoff DD.

Ann Oncol. 2001 Nov;12(11):1631-41.

PMID:
11822765
34.

Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer.

Socinski MA, Sandler AB, Miller LL, Locker PK, Hanover CK, Elfring GL, Israel VK, Pirotta N, Natale RB.

J Clin Oncol. 2001 Feb 15;19(4):1078-87.

PMID:
11181672
35.

Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.

Saltz LB, Douillard JY, Pirotta N, Alakl M, Gruia G, Awad L, Elfring GL, Locker PK, Miller LL.

Oncologist. 2001;6(1):81-91.

36.

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL.

N Engl J Med. 2000 Sep 28;343(13):905-14.

37.

Effects of treatment with clindamycin hydrochloride on progression of canine periodontal disease after ultrasonic scaling.

Nielsen D, Walser C, Kodan G, Chaney RD, Yonkers T, VerSteeg JD, Elfring G, Slots J.

Vet Ther. 2000 Summer;1(3):150-8.

PMID:
19757577
38.

Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.

Pitot HC, Goldberg RM, Reid JM, Sloan JA, Skaff PA, Erlichman C, Rubin J, Burch PA, Adjei AA, Alberts SA, Schaaf LJ, Elfring G, Miller LL.

Clin Cancer Res. 2000 Jun;6(6):2236-44.

39.

Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer.

DeVore RF, Johnson DH, Crawford J, Garst J, Dimery IW, Eckardt J, Eckhardt SG, Elfring GL, Schaaf LJ, Hanover CK, Miller LL.

J Clin Oncol. 1999 Sep;17(9):2710-20.

PMID:
10561345
40.

Irinotecan therapy in adults with recurrent or progressive malignant glioma.

Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Colvin OM, Provenzale JM, McLendon RE, Bigner DD, Cokgor I, Haglund M, Rich J, Ashley D, Malczyn J, Elfring GL, Miller LL.

J Clin Oncol. 1999 May;17(5):1516-25.

PMID:
10334539
41.

A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.

Rothenberg ML, Cox JV, DeVore RF, Hainsworth JD, Pazdur R, Rivkin SE, Macdonald JS, Geyer CE Jr, Sandbach J, Wolf DL, Mohrland JS, Elfring GL, Miller LL, Von Hoff DD.

Cancer. 1999 Feb 15;85(4):786-95.

PMID:
10091755
42.

Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors.

Drengler RL, Kuhn JG, Schaaf LJ, Rodriguez GI, Villalona-Calero MA, Hammond LA, Stephenson JA Jr, Hodges S, Kraynak MA, Staton BA, Elfring GL, Locker PK, Miller LL, Von Hoff DD, Rothenberg ML.

J Clin Oncol. 1999 Feb;17(2):685-96.

PMID:
10080615
43.

Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors.

Saltz LB, Spriggs D, Schaaf LJ, Schwartz GK, Ilson D, Kemeny N, Kanowitz J, Steger C, Eng M, Albanese P, Semple D, Hanover CK, Elfring GL, Miller LL, Kelsen D.

J Clin Oncol. 1998 Dec;16(12):3858-65.

PMID:
9850031
44.

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA 3rd, Nelson J, Hilsenbeck SG, Rodriguez GI, Thurman AM, Smith LS, Eckhardt SG, Weiss GR, Elfring GL, Rinaldi DA, Schaaf LJ, Von Hoff DD.

J Clin Oncol. 1996 Apr;14(4):1128-35.

PMID:
8648367
45.

Phase I study of adozelesin (U-73,975) in patients with solid tumors.

Shamdas GJ, Alberts DS, Modiano M, Wiggins C, Power J, Kasunic DA, Elfring GL, Earhart RH.

Anticancer Drugs. 1994 Feb;5(1):10-4.

PMID:
8186423
46.

Role of cyclooxygenase products of arachidonic acid metabolism in Ascaris antigen-induced bronchoconstriction in sensitized dogs.

Richards IM, Griffin RL, Oostveen JA, Elfring G, Conder GA.

J Pharmacol Exp Ther. 1988 May;245(2):735-41.

PMID:
3130478
47.

Plasma and cerebrospinal fluid pharmacokinetics of acivicin in Ommaya reservoir-bearing rhesus monkeys.

McGovren JP, Stewart JC, Elfring GL, Smith RB, Soares N, Wood JH, Poplack DG, Von Hoff DD.

Cancer Treat Rep. 1982 Jun;66(6):1333-41.

PMID:
7083237
48.

The efficient use of NONLIN for unbalanced multiple dose data.

Elfring GL, Metzler CM.

J Pharmacokinet Biopharm. 1981 Aug;9(4):497-501.

PMID:
7310647
49.

Curve fitting and modeling in pharmacokinetics: a response.

Metzler CM, Elfring GL.

J Pharmacokinet Biopharm. 1978 Oct;6(5):443-6. No abstract available.

PMID:
731410
50.

The use of circulating rosette-forming cells as a guide to determination of ATG dose (dose-by-rosette).

Byfield PE, Barth CL, Brodie JA, Cosimi AB, Dienst SG, Elberg AJ, Elfring GL, Hardy MA, Hayashi H, Kountz SL, Lamborn KR, Loughman BE, Sakai A, Satoh PS, Zielinski CM, Wechter WJ.

Transplant Proc. 1978 Sep;10(3):627-31. No abstract available.

PMID:
362648

Supplemental Content

Loading ...
Support Center